Daily Market Recap – 2025-09-30
On September 30, U.S. small-cap and micro-cap stocks rallied sharply, driving double- and triple-digit gains in a number of heavily traded issues. Market participants showed continued interest in speculative names, particularly those with recent regulatory filings or biotech exposure. Volume was robust across the board, with several tickers trading tens of millions of shares.
Below is an overview of key movers, including opening prices (prior-close), current intraday prices, trading volume, and percentage gains:
| Ticker | ATTN Price | Current Price | Volume | Price Change % |
|---|---|---|---|---|
| BENF | 0.3986 | 0.8346 | 357,710,546 | 109.42% |
| EPOW | 1.1353 | 1.4100 | 21,323,434 | 24.22% |
| VIVK | 0.2634 | 0.4280 | 41,315,914 | 62.55% |
| SKYQ | 0.4001 | 0.5550 | 73,078,264 | 38.72% |
| PATH | 11.8321 | 13.4599 | 42,231,901 | 13.79% |
| WOLF | 22.2932 | 28.1816 | 27,060,474 | 26.45% |
| IBG | 3.0568 | 4.3366 | 45,170,524 | 41.95% |
| SPRC | 4.4800 | 5.7100 | 18,759,615 | 27.47% |
| CLIK | 0.1918 | 0.3068 | 44,023,799 | 60.00% |
| NUVB | 3.0612 | 3.6529 | 11,294,538 | 19.34% |
| ZURA | 2.9072 | 4.3200 | 27,059,574 | 48.56% |
| SCYX | 0.6419 | 0.8189 | 2,270,857 | 27.50% |
| ZYBT | 1.2463 | 2.5598 | 6,329,493 | 105.39% |
| APDN | 3.2276 | 3.8360 | 658,905 | 18.93% |
| ANAB | 23.5538 | 30.6200 | 2,876,276 | 30.00% |
| DLXY | 0.1653 | 1.1103 | 4,986,790 | 572.00% |
| BKKT | 25.1366 | 33.1494 | 6,019,254 | 31.84% |
| AMBC | 6.9463 | 8.3400 | 1,653,458 | 20.10% |
| DPRO | 6.6906 | 8.1400 | 39,827,138 | 21.66% |
| MTEN | 3.3569 | 5.8400 | 192,149 | 74.01% |
Market Trends and Patterns
The session was characterized by heightened volatility in lower‐priced shares. A handful of names more than doubled, with DLXY leading the advance at a 572% gain following an unexpected regulatory update. Biotechnology‐related tickers such as BENF, ZYBT and VIVK also enjoyed strong upside, coinciding with fresh SEC filings and proposed corporate actions.
Volume distribution reveals both speculative retail interest and institutional activity. Stocks trading under $1 attracted the highest share counts, while mid‐cap issues like PATH and IBG logged tens of millions of shares exchanged. Price momentum was widespread, with every name in the table marking gains above 13%.
Sector‐wise, the biotech and specialty finance segments saw the greatest strength. Several companies released Form 8-K or S-3 registrations within the past week, which appears to have catalyzed renewed buying. Meanwhile, general market indices remained relatively flat, suggesting a rotation into higher-beta names rather than broad-based risk-taking.
Significant Movers and Volume Surges
• DLXY soared from an ATTN price of $0.1653 to $1.1103, accounting for a 572% leap on nearly 5 million shares traded.
• BENF more than doubled intraday, climbing 109.4% on exceptionally heavy volume (357 million shares).
• ZYBT and MTEN each gained over 100% and 74% respectively, buoyed by fresh disclosures and strategic announcements.
• VIVK and CLIK rallied 62.6% and 60.0% as speculative momentum extended to sub-$0.50 equities.
• DPRO, IBG and PATH recorded high‐teens to mid‐40s percentage advances alongside volumes exceeding 20 million shares.
Biotech stocks by CDC
TL;DR
- U.S. micro-caps and small-caps surged, with all 20 tracked tickers posting gains above 13%.
- DLXY led the pack, up 572% on 4.9 million shares after a regulatory filing.
- BENF and ZYBT climbed over 100%, while MTEN, VIVK and CLIK rallied strongly in the biotech/spec segment.
- High volume names included BENF (357 M), DPRO (39.8 M), IBG (45.2 M) and PATH (42.2 M).
- Market attention remains on speculative filings and late-stage disclosure catalysts.
